Home > Dermatology > AAD 2018 > Psoriasis: an update > Oral therapeutics, supersaturation and excimer laser

Oral therapeutics, supersaturation and excimer laser

Presented By
Dr John Koo, University of California San Francisco, USA
Conference
AAD 2018
Trial
ESTEEM 2
Dr John Koo, of the Phototherapy and Skin Treatment Clinic at the University of California San Francisco, gave an update on new data on oral therapeutics in psoriasis [1]. Apremilast appears to have lower efficacy than some biologic agents. However, its ease of administration as an oral agent, coupled with a mild side-effect profile, make it an attractive option for many psoriasis patients. A poster presented at the annual meeting of the European Academy of Dermatology and Veneorology (EADV) in Geneva provided more insight into the mode of action of this small molecule: it assessed the influence of apremilast on different cytokines compared to placebo [2]. Data came from the ESTEEM 2 trial, which confirmed the therapeutic concept that apremilast works as a cytokine modulator. It has a distinct effect on the proinflammatory cytokines IL-17A, IL-17F and IL-22, but lowers TNF-α to only a minimal amount. “I think it is therefore a good idea to combine apremilast ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on